title: Quantitative X-ray computed tomography peritoneography in malignant peritoneal mesothelioma patients receiving intraperitoneal chemotherapy.
abstract: BACKGROUND
  Intraperitoneal chemotherapy is used to treat peritoneal surface-spreading malignancies. We sought to determine whether volume and surface area of the intraperitoneal chemotherapy compartments are associated with overall survival and posttreatment glomerular filtration rate (GFR) in malignant peritoneal mesothelioma (MPM) patients.
  
  
  METHODS
  Thirty-eight MPM patients underwent X-ray computed tomography peritoneograms during outpatient intraperitoneal chemotherapy. We calculated volume and surface area of contrast-filled compartments by semiautomated computer algorithm. We tested whether these were associated with overall survival and posttreatment GFR.
  
  
  RESULTS
  Decreased likelihood of mortality was associated with larger surface areas (p = 0.0201) and smaller contrast-filled compartment volumes (p = 0.0341), controlling for age, sex, histologic subtype, and presence of residual disease >0.5 cm postoperatively. Larger volumes were associated with higher posttreatment GFR, controlling for pretreatment GFR, body surface area, surface area, and the interaction between body surface area and volume (p = 0.0167).
  
  
  CONCLUSIONS
  Computed tomography peritoneography is an appropriate modality to assess for maldistribution of intraperitoneal chemotherapy. In addition to identifying catheter failure and frank loculation, quantitative analysis of the contrast-filled compartment's surface area and volume may predict overall survival and cisplatin-induced nephrotoxicity. Prospective studies should be undertaken to confirm and extend these findings to other diseases, including advanced ovarian carcinoma.
authors.affiliation: Division of Medical Oncology, Department of Medicine, Columbia University Medical Center, New York, NY, USA.
authors.forename: Joshua C
authors.initials: JC
authors.lastname: Leinwand
authors.forename: Binsheng
authors.initials: B
authors.lastname: Zhao
authors.forename: Xiaotao
authors.initials: X
authors.lastname: Guo
authors.forename: Saravanan
authors.initials: S
authors.lastname: Krishnamoorthy
authors.forename: Jing
authors.initials: J
authors.lastname: Qi
authors.forename: Joseph H
authors.initials: JH
authors.lastname: Graziano
authors.forename: Vesna N
authors.initials: VN
authors.lastname: Slavkovic
authors.forename: Gleneara E
authors.initials: GE
authors.lastname: Bates
authors.forename: Sharyn N
authors.initials: SN
authors.lastname: Lewin
authors.forename: John D
authors.initials: JD
authors.lastname: Allendorf
authors.forename: John A
authors.initials: JA
authors.lastname: Chabot
authors.forename: Lawrence H
authors.initials: LH
authors.lastname: Schwartz
authors.forename: Robert N
authors.initials: RN
authors.lastname: Taub
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D010478:Chemotherapy, Cancer, Regional Perfusion; D002945:Cisplatin / Q000008:administration & dosage / Q000493:pharmacokinetics*; D005260:Female; D005500:Follow-Up Studies; D005919:Glomerular Filtration Rate; D006801:Humans; D007274:Injections, Intraperitoneal; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000401:mortality; D008297:Male; D008654:Mesothelioma / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000401:mortality; D000086002:Mesothelioma, Malignant; D008875:Middle Aged; D018365:Neoplasm, Residual / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000401:mortality; D010534:Peritoneal Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000401:mortality; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D014018:Tissue Distribution; D014057:Tomography, X-Ray Computed; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin